The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors: Results on safety, pharmacokinetics, and anti-tumor activity.
 
Apostolia Tsimberidou
Consulting or Advisory Role - Avstera; BioEclipse Therapeutics; BrYet; Macrogenics; Nex-I; Vincerx Pharma
Research Funding - Abbvie (Inst); Agenus (Inst); Anaveon (Inst); BrYet; IMMATICS (Inst); Macrogenics (Inst); Novocure (Inst); OBI Pharma (Inst); Orionis (Inst); Parker Institute for Cancer Immunotherapy (Inst); Tachyon (Inst); Tempus (Inst); Tempus (Inst); Tvardi Therapeutics (Inst); Vividion Therapeutics (Inst)
 
Farshid Dayyani
Consulting or Advisory Role - AstraZeneca; Eisai
Speakers' Bureau - Astellas Pharma; Exelixis; ipsen; SERVIER; Sirtex Medical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Ipsen (Inst); Merck (Inst); Taiho Pharmaceutical (Inst)
 
David Sommerhalder
Employment - Texas Oncology
Stock and Other Ownership Interests - Next Oncology; Texas Oncology/US Oncology
Honoraria - Syneos Health
Consulting or Advisory Role - Nimbus Therapeutics; Revolution Medicines
Research Funding - Abbvie (Inst); Acrivon Therapeutics (Inst); ADC Therapeutics (Inst); Aprea Therapeutics (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); Biomea Fusion (Inst); BioNTech SE (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Day One Biopharmaceuticals (Inst); Dicerna (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Haihe Pharmaceutical (Inst); IconOVir Bio (Inst); Immuneering (Inst); IMPAC Medical Systems (Inst); Incendia Pharmaceuticals AB (Inst); Kura Oncology (Inst); MediLink (Inst); Mirati Therapeutics (Inst); ModeX Therapeutics (Inst); Monopteros Therapeutics (Inst); Navire (Inst); NGM Biopharmaceuticals (Inst); Nimbus Therapeutics (Inst); Novo Nordisk (Inst); OBI Pharma (Inst); OncoResponse (Inst); Pfizer (Inst); Revolution Medicines (Inst); Step Pharma (Inst); Symphogen (Inst); Tachyon Therapeutics (Inst); Teon Therapeutics (Inst); Tyligand Bioscience (Inst); Vincera Pharma/Vincerx Pharma (Inst); Vividion Therapeutics (Inst); ZielBio (Inst); Zymeworks (Inst)
 
Andrae Vandross
No Relationships to Disclose
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - Arcus Biosciences (Inst); AstraZeneca (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Stemline Therapeutics (Inst); Takeda (Inst)
Research Funding - 1200 Pharma (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Elicio Therapeutics (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Fog Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); IMPAC Medical Systems (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Leap Therapeutics (Inst); Neogene (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Seagen (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Takeda (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Cesar Perez
Consulting or Advisory Role - BeiGene; EMD Serono; Pfizer
Research Funding - Accutar Biotech (Inst); ADANATE Biotechnology (Inst); Artios (Inst); BeiGene (Inst); Coherent Biopharma (Inst); Compass Therapeutics (Inst); Corvus Pharmaceuticals (Inst); DualityBio (Inst); Elevation Oncology (Inst); Elpiscience (Inst); Genentech (Inst); Hyamab (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Loxo/Lilly (Inst); Merus (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Ribon Therapeutics (Inst); Seagen (Inst); Systimmune (Inst); Tachyon Therapeutics (Inst); Tallac Therapeutics (Inst); Xilio Therapeutics (Inst); Zhuhai Yufan Biotechnologies (Inst)
 
Chandtip Chandhasin
Employment - Tachyon Therapeutics
 
Yiyun Dai
Employment - Tachyon Therapeutics
 
Shirley Tu
Employment - Tachyon Therapeutics
 
Ivan King
Employment - Tachyon Therapeutics
 
Frank Perabo
Employment - Tachyon Therapeutics
Leadership - Tachyon Therapeutics
Stock and Other Ownership Interests - Alnylam; Aurinia Pharmaceuticals; Black Diamond Therapeutics; Chimerix; Janux Therapeutics; JNJ; MAIA Biotechnology; Tachyon Therapeutics; Travere Therapeutics; Turning Point Therapeutics; Viking Therapeutics
Consulting or Advisory Role - Hinova Pharmaceuticals; Pattern Pharma; Purespring Therapeutics; Radius Health
Patents, Royalties, Other Intellectual Property - KDM4 patents